We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Bristol Myers Squibb Co | NYSE:BMY | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.30 | 0.68% | 44.24 | 44.47 | 43.728 | 43.87 | 13,247,479 | 00:58:24 |
Merck & Co.'s immunotherapy cancer drug Keytruda received U.S. Food and Drug Administration approval as a first-line treatment for certain lung cancer patients.
The approval is for patients with metastatic non-small cell lung cancer whose tumors have high PD-L1 expression, with no EGFR or ALK genomic tumor aberrations.
The new indication means Keytruda can be an initial treatment instead of chemotherapy for these patients.
Additionally, the FDA approved a Keytruda labeling update for second-line treatment for certain patients, reflecting favorable data from the Keynote-010 trial.
Keytruda, or pembrolizumab, was first approved in 2014 for the treatment of melanoma. The Keytruda clinical development program includes more than 30 tumor types.
In October 2015, the drug was cleared for use as a second-line treatment for certain patients with non-small-cell lung cancer whose disease continued to worsen after the patient received chemotherapy or other drugs.
A Merck study published earlier this month showed that people who received Keytruda as their first treatment lived longer on average than those who received chemotherapy.
In a separate study of another immunotherapy drug, Bristol-Myers Squibb Co.'s Opdivo failed to significantly prolong survival beyond chemotherapy. Bristol-Myers tested Opdivo as a first-line treatment in a broader pool of lung cancer patients because the study also included those who had relatively low levels of PD-L1 in their tumors.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
October 24, 2016 21:25 ET (01:25 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Bristol Myers Squibb Chart |
1 Month Bristol Myers Squibb Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions